# AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

Study · id `cardio:ct-nct05035277` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05035277](<https://clinicaltrials.gov/study/NCT05035277>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05035277

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

## Technical summary

Registry record NCT05035277. Randomized; single masking; primary purpose prevention. Start 2021-12-04 (actual); primary completion 2026-06-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 360 participants (enrolled count; ClinicalTrials.gov record NCT05035277, source copy `cardio:ctgov-nct05035277-2026-06-09`, retrieved 2026-10-26)
- Started: 2021-12-04 (actual) (ClinicalTrials.gov record NCT05035277, source copy `cardio:ctgov-nct05035277-2026-06-09`, retrieved 2026-10-26)
- Primary completion: 2026-06-05 (actual) (ClinicalTrials.gov record NCT05035277, source copy `cardio:ctgov-nct05035277-2026-06-09`, retrieved 2026-10-26)
- Completion: 2026-06-05 (actual) (ClinicalTrials.gov record NCT05035277, source copy `cardio:ctgov-nct05035277-2026-06-09`, retrieved 2026-10-26)
- Countries: Norway (ClinicalTrials.gov record NCT05035277, source copy `cardio:ctgov-nct05035277-2026-06-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05035277-2026-06-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
- Acronym: ACASA-TAVI
- Condition: Aortic Stenosis
- Intervention (Drug): Acetylsalicylic acid
- Intervention (Drug): Apixaban
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Edoxaban
- Lead sponsor: Oslo University Hospital
- Lead sponsor class: OTHER
- Collaborator: University of Oslo
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry lists this organization as the lead sponsor: Oslo University Hospital (`cardio:org-oslo-university-hospital`)
- Registry lists this organization as a collaborator: University of Oslo (`cardio:org-university-of-oslo`)

## Provenance

Content hash: fe4644b1a7b9205494c33172a213708294d4256708d9b99cf3c6c80fef063cb4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
